Back to results
US 2025/0082748 A1Published application
Human cytomegalovirus rna vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Shinu John, Kambiz Mousavi
Life of this patent
Estimating the term…
Abstract
The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Claims21
1-104. (canceled)
A messenger ribonucleic acid (mRNA) vaccine comprising:
- (a) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an open reading frame (ORF) encoding an hCMV gH protein, a 3′ UTR, and a poly(A) tail;
- (b) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an ORF encoding an hCMV gL protein, a 3′ UTR, and a poly(A) tail;
- (c) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an ORF encoding an hCMV UL128 protein, a 3′ UTR, and a poly(A) tail;
- (d) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an ORF encoding an hCMV UL130 protein, a 3′ UTR, and a poly(A) tail;
- (e) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an ORF encoding an hCMV UL131 protein, a 3′ UTR, and a poly(A) tail;
- and
- a lipid nanoparticle;
- wherein 100% of uracil nucleosides in the ORF of the mRNA polynucleotides of (b) to (e) are N1-methylpseudouridine.
5 more elements
A method of inducing an immune response against hCMV in a subject comprising administering to the subject an mRNA vaccine comprising:
- (a) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an open reading frame (ORF) encoding an hCMV gH protein, a 3′ UTR, and a poly(A) tail;
- (b) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an ORF encoding an hCMV gL protein, a 3′ UTR, and a poly(A) tail;
- (c) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an ORF encoding an hCMV UL128 protein, a 3′ UTR, and a poly(A) tail;
- (d) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an ORF encoding an hCMV UL130 protein, a 3′ UTR, and a poly(A) tail;
- (e) an mRNA polynucleotide having from 5′ to 3′ a 5′UTR, an ORF encoding an hCMV UL131 protein, a 3′ UTR, and a poly(A) tail;
- and
- a lipid nanoparticle;
- wherein 100% of uracil nucleosides in the ORF of the mRNA polynucleotides of (a) to (e) are N1-methylpseudouridine;
- in an amount effective to produce an immune response against hCMV in the subject.
6 more elements
The method of claim 123, wherein the mRNA vaccine further comprises:
- (f) an mRNA polynucleotide having, from 5′ to 3′, a 5′ UTR, an ORF encoding an hCMV gB protein, a 3′ UTR, and a poly(A) tail, wherein an hCMV gB protein comprises the amino acid sequence of SEQ ID NO:
- 69 and wherein 100% of uracil nucleosides in the ORF of the mRNA polynucleotide of (f) are N1-methylpseudouridine.
Dependencies are inferred from the claim text.